Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? Savara's Molbreevi BLA for autoimmune PAP was rejected by the FDA due to incomplete CMC data; the company plans to resubmit in Q4 2025.
Here are the top movers in Tuesday's session. Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Let's have a look at the top gainers and losers in the middle of the day of today's session. Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
SVRA Stock Earnings: Savara Misses EPS for Q2 2024 SVRA stock results show that Savara missed analyst estimates for earnings per share the second quarter of 2024.
SVRA Stock Earnings: Savara Misses EPS for Q1 2024 SVRA stock results show that Savara missed analyst estimates for earnings per share the first quarter of 2024.
There are notable gap-ups and gap-downs in today's session. In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.
Stay updated with the stocks that are on the move in today's pre-market session. Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
SVRA Stock Earnings: Savara Beats EPS for Q4 2023 SVRA stock results show that Savara beat analyst estimates for earnings per share the fourth quarter of 2023.
Why Is Respiratory Disease-Focused Savara Stock Trading Higher On Wednesday? Savara announces Phase 3 IMPALA-2 trial results for molgramostim in treating autoimmune pulmonary alveolar proteinosis. The inhaled GM-CSF met primary and secondary endpoints, showing significant improvements.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
3 Penny Stocks Poised for Major Upside Over the Next 5 Years These three penny stocks to buy are poised for major upside over the medium-term, for various reasons worth exploring.
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year.
5 OTC Stocks With The Potential To Explode In 2024 Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.
3 Penny Stocks to Provide 1,000% Returns Over the Next Decade Consider three intriguing penny stocks for investors looking to add a bit more risk to their portfolio in times like these.
The 3 Best Penny Stocks to Buy Now: September 2023 When all the focus lies on the largest names of the economy, these best penny stocks to buy offer a great risk/reward ratio.
Johnson & Johnson, Zions Bancorporation, Heritage-Crystal Clean And Other Big Stocks Moving Higher On Thursday U.S. stocks traded mixed, with the Dow Jones gaining over 200 points on Thursday. Here are some big stocks recording gains in today’s session. Tarsus Pharmaceuticals, Inc. (
NASDAQ: TARS ) shares rose 12.3% to $22.59.
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session.
